Ticker Details
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
IPO Date:	April 2, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$82.43B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$4.38 | 1.80%
Avg Daily Range (30 D):	$11.46 | 1.49%
Avg Daily Range (90 D):	$10.33 | 1.44%

Institutional Daily Volume
Avg Daily Volume:	.67M
Avg Daily Volume (30 D):	.64M
Avg Daily Volume (90 D):	.73M

Trade Size
Avg Trade Size (Sh.):	60
Avg Trade Size (Sh.) (30 D):	20
Avg Trade Size (Sh.) (90 D):	20

Institutional Trades
Total Institutional Trades:	11,611
Avg Institutional Trade:	$19.31M
Avg Institutional Trade (30 D):	$59.27M
Avg Institutional Trade (90 D):	$49.75M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$37.97M
Avg Closing Trade (30 D):	$102.6M
Avg Closing Trade (90 D):	$99.19M
Avg Closing Volume:	75.35K

News

Feb 25, 2026 @ 12:16 AM 2 Reasons Regeneron Stock Could Crush the Market f... Source: Prosper Junior Bakiny

Feb 24, 2026 @ 6:47 PM Regeneron, Sanofi Blockbuster Dupixent Scores FDA ... Source: Vandana Singh

Feb 13, 2026 @ 6:45 PM CRISPR Therapeutics Spotlights Momentum For Lead G... Source: Vandana Singh

Feb 13, 2026 @ 3:00 PM Decoding Our DNA: The Human Impact Behind SNP Geno... Source: Towards Healthcare

Feb 13, 2026 @ 1:23 PM Sanofi Stock Near 52-Week Low As Leadership Shakeu... Source: Vandana Singh

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$43.07	$8.24	$43.07
Diluted EPS	$41.48	$7.87	$41.48
Revenue	$14.34B	$3.88B	$14.34B
Gross Profit
Net Income / Loss	$4.5B	$844.6M	$4.5B
Operating Income / Loss	$3.58B	$879.9M	$3.58B
Cost of Revenue
Net Cash Flow	$634.7M	$610.6M	$634.7M
PE Ratio	18.62